PharmaCyte Net Receivables vs Short Term Debt Analysis

PMCB Stock

USD 1.62 0.05 2.99%

PharmaCyte Biotech financial indicator trend analysis is much more than just breaking down PharmaCyte Biotech prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether PharmaCyte Biotech is a good investment. Please check the relationship between PharmaCyte Biotech Net Receivables and its Short Term Debt accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PharmaCyte Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For information on how to trade PharmaCyte Stock refer to our How to Trade PharmaCyte Stock guide.

Net Receivables vs Short Term Debt

Net Receivables vs Short Term Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of PharmaCyte Biotech Net Receivables account and Short Term Debt. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between PharmaCyte Biotech's Net Receivables and Short Term Debt is -0.11. Overlapping area represents the amount of variation of Net Receivables that can explain the historical movement of Short Term Debt in the same time period over historical financial statements of PharmaCyte Biotech, assuming nothing else is changed. The correlation between historical values of PharmaCyte Biotech's Net Receivables and Short Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Receivables of PharmaCyte Biotech are associated (or correlated) with its Short Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Term Debt has no effect on the direction of Net Receivables i.e., PharmaCyte Biotech's Net Receivables and Short Term Debt go up and down completely randomly.

Correlation Coefficient

-0.11

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Net Receivables

Short Term Debt

Most indicators from PharmaCyte Biotech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into PharmaCyte Biotech current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PharmaCyte Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For information on how to trade PharmaCyte Stock refer to our How to Trade PharmaCyte Stock guide.The current year's Sales General And Administrative To Revenue is expected to grow to 122.83, whereas Selling General Administrative is forecasted to decline to about 4.8 M.

PharmaCyte Biotech fundamental ratios Correlations

	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Retained Earnings	Common Stock Total Equity	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Common Stock	Total Assets	Short Long Term Debt Total	Other Liab	Property Plant And Equipment Net	Net Debt	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Long Term Debt	Cash And Short Term Investments	Non Current Liabilities Total	Inventory	Total Current Assets	Property Plant Equipment	Net Receivables	Short Term Investments
Other Current Liab		0.96	0.24	-0.28	-0.4	-0.26	0.29	0.99	-0.4	0.45	-0.07	0.93	0.42	-0.38	0.27	0.41	0.65	0.98	-0.2	0.41	0.96	-0.2	0.41	0.75	-0.01	0.41
Total Current Liabilities	0.96		0.15	-0.15	-0.39	-0.3	0.19	0.96	-0.38	0.35	0.19	0.86	0.44	-0.29	0.46	0.32	0.5	0.94	-0.25	0.32	0.9	-0.25	0.33	0.73	0.05	0.44
Total Stockholder Equity	0.24	0.15		-0.56	-0.56	-0.28	0.84	0.25	-0.55	0.98	-0.28	0.29	0.26	-0.99	-0.22	0.98	0.44	0.26	-0.2	0.98	0.3	-0.2	0.98	0.32	0.13	0.26
Retained Earnings	-0.28	-0.15	-0.56		-0.01	-0.34	-0.72	-0.28	-0.02	-0.58	0.52	-0.34	-0.74	0.54	0.09	-0.53	-0.83	-0.28	0.7	-0.54	-0.33	0.7	-0.53	-0.69	-0.62	-0.73
Common Stock Total Equity	-0.4	-0.39	-0.56	-0.01		0.41	-0.1	-0.42	1.0	-0.61	-0.08	-0.41	0.08	0.61	0.04	-0.62	-0.11	-0.43	-0.2	-0.61	-0.43	-0.19	-0.62	-0.14	0.29	0.09
Common Stock Shares Outstanding	-0.26	-0.3	-0.28	-0.34	0.41		-0.24	-0.26	0.41	-0.32	-0.2	-0.22	0.09	0.33	-0.31	-0.34	0.07	-0.26	-0.15	-0.33	-0.23	-0.15	-0.34	-0.04	0.2	0.09
Other Stockholder Equity	0.29	0.19	0.84	-0.72	-0.1	-0.24		0.3	-0.09	0.84	-0.37	0.33	0.5	-0.82	-0.07	0.82	0.63	0.3	-0.44	0.82	0.34	-0.44	0.82	0.52	0.37	0.5
Total Liab	0.99	0.96	0.25	-0.28	-0.42	-0.26	0.3		-0.41	0.46	-0.01	0.95	0.4	-0.39	0.28	0.41	0.66	1.0	-0.18	0.41	0.99	-0.18	0.42	0.75	-0.04	0.4
Common Stock	-0.4	-0.38	-0.55	-0.02	1.0	0.41	-0.09	-0.41		-0.6	-0.08	-0.4	0.09	0.6	0.04	-0.61	-0.11	-0.43	-0.2	-0.6	-0.42	-0.2	-0.61	-0.13	0.29	0.09
Total Assets	0.45	0.35	0.98	-0.58	-0.61	-0.32	0.84	0.46	-0.6		-0.26	0.48	0.33	-1.0	-0.14	1.0	0.55	0.47	-0.22	1.0	0.5	-0.22	1.0	0.46	0.11	0.32
Short Long Term Debt Total	-0.07	0.19	-0.28	0.52	-0.08	-0.2	-0.37	-0.01	-0.08	-0.26		-0.14	-0.08	0.25	0.65	-0.23	-0.54	-0.05	0.05	-0.23	-0.12	0.05	-0.23	-0.13	-0.02	-0.08
Other Liab	0.93	0.86	0.29	-0.34	-0.41	-0.22	0.33	0.95	-0.4	0.48	-0.14		0.37	-0.42	0.16	0.44	0.7	0.95	-0.13	0.44	0.96	-0.13	0.44	0.75	-0.08	0.33
Property Plant And Equipment Net	0.42	0.44	0.26	-0.74	0.08	0.09	0.5	0.4	0.09	0.33	-0.08	0.37		-0.27	0.47	0.28	0.66	0.37	-0.97	0.28	0.35	-0.97	0.28	0.89	0.89	0.99
Net Debt	-0.38	-0.29	-0.99	0.54	0.61	0.33	-0.82	-0.39	0.6	-1.0	0.25	-0.42	-0.27		0.17	-1.0	-0.48	-0.4	0.18	-1.0	-0.43	0.18	-1.0	-0.4	-0.08	-0.27
Accounts Payable	0.27	0.46	-0.22	0.09	0.04	-0.31	-0.07	0.28	0.04	-0.14	0.65	0.16	0.47	0.17		-0.15	0.0	0.22	-0.45	-0.16	0.16	-0.45	-0.15	0.41	0.42	0.46
Cash	0.41	0.32	0.98	-0.53	-0.62	-0.34	0.82	0.41	-0.61	1.0	-0.23	0.44	0.28	-1.0	-0.15		0.49	0.43	-0.18	1.0	0.45	-0.18	1.0	0.41	0.08	0.28
Non Current Assets Total	0.65	0.5	0.44	-0.83	-0.11	0.07	0.63	0.66	-0.11	0.55	-0.54	0.7	0.66	-0.48	0.0	0.49		0.67	-0.52	0.49	0.72	-0.52	0.49	0.81	0.35	0.66
Non Currrent Assets Other	0.98	0.94	0.26	-0.28	-0.43	-0.26	0.3	1.0	-0.43	0.47	-0.05	0.95	0.37	-0.4	0.22	0.43	0.67		-0.14	0.43	0.99	-0.14	0.43	0.73	-0.08	0.36
Long Term Debt	-0.2	-0.25	-0.2	0.7	-0.2	-0.15	-0.44	-0.18	-0.2	-0.22	0.05	-0.13	-0.97	0.18	-0.45	-0.18	-0.52	-0.14		-0.18	-0.12	1.0	-0.18	-0.75	-0.97	-0.97
Cash And Short Term Investments	0.41	0.32	0.98	-0.54	-0.61	-0.33	0.82	0.41	-0.6	1.0	-0.23	0.44	0.28	-1.0	-0.16	1.0	0.49	0.43	-0.18		0.45	-0.18	1.0	0.41	0.08	0.28
Non Current Liabilities Total	0.96	0.9	0.3	-0.33	-0.43	-0.23	0.34	0.99	-0.42	0.5	-0.12	0.96	0.35	-0.43	0.16	0.45	0.72	0.99	-0.12	0.45		-0.12	0.46	0.72	-0.11	0.34
Inventory	-0.2	-0.25	-0.2	0.7	-0.19	-0.15	-0.44	-0.18	-0.2	-0.22	0.05	-0.13	-0.97	0.18	-0.45	-0.18	-0.52	-0.14	1.0	-0.18	-0.12		-0.18	-0.75	-0.97	-0.97
Total Current Assets	0.41	0.33	0.98	-0.53	-0.62	-0.34	0.82	0.42	-0.61	1.0	-0.23	0.44	0.28	-1.0	-0.15	1.0	0.49	0.43	-0.18	1.0	0.46	-0.18		0.41	0.08	0.28
Property Plant Equipment	0.75	0.73	0.32	-0.69	-0.14	-0.04	0.52	0.75	-0.13	0.46	-0.13	0.75	0.89	-0.4	0.41	0.41	0.81	0.73	-0.75	0.41	0.72	-0.75	0.41		0.6	0.87
Net Receivables	-0.01	0.05	0.13	-0.62	0.29	0.2	0.37	-0.04	0.29	0.11	-0.02	-0.08	0.89	-0.08	0.42	0.08	0.35	-0.08	-0.97	0.08	-0.11	-0.97	0.08	0.6		0.9
Short Term Investments	0.41	0.44	0.26	-0.73	0.09	0.09	0.5	0.4	0.09	0.32	-0.08	0.33	0.99	-0.27	0.46	0.28	0.66	0.36	-0.97	0.28	0.34	-0.97	0.28	0.87	0.9

Click cells to compare fundamentals

PharmaCyte Biotech Account Relationship Matchups

PharmaCyte Biotech fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Other Current Liab	816.6K	552.5K	499.0K	400.2K	6.7M	7.0M
Total Current Liabilities	1.0M	724.8K	704.4K	586.6K	7.4M	7.8M
Total Stockholder Equity	5.1M	6.7M	89.9M	72.7M	39.5M	41.5M
Retained Earnings	(103.9M)	(107.4M)	(111.6M)	(116.0M)	(115.6M)	(109.8M)
Common Stock Total Equity	101.3K	118.6K	163.9K	159.0	182.85	173.71
Common Stock Shares Outstanding	1.4B	1.7B	15.5M	19.5M	9.6M	9.1M
Other Stockholder Equity	108.8M	(20.4K)	201.6M	188.7M	143.3M	150.5M
Total Liab	1.1M	724.8K	704.4K	586.6K	20.4M	21.4M
Common Stock	163.9K	159.0	2.1K	2.2K	2.2K	2.1K
Total Assets	6.2M	7.4M	90.6M	73.3M	59.9M	62.9M
Net Debt	(819.7K)	(2.2M)	(85.4M)	(68.0M)	(50.2M)	(47.7M)
Accounts Payable	185.8K	172.3K	205.4K	128.3K	389.4K	322.7K
Cash	894.9K	2.2M	85.4M	68.0M	50.2M	52.7M
Cash And Short Term Investments	2.5M	2.2M	85.4M	68.0M	50.2M	52.7M
Liabilities And Stockholders Equity	6.2M	7.4M	90.6M	73.3M	59.9M	62.9M
Non Current Liabilities Total	121.9K	46.3K	172.3K	205.4K	13.0M	13.6M
Total Current Assets	1.0M	2.3M	85.5M	68.1M	50.4M	53.0M
Other Current Assets	(1.4M)	73.1K	188.3K	215.4K	259.8K	241.3K
Accumulated Other Comprehensive Income	(21.7K)	(20.4K)	(15.8K)	(23.0K)	(23.5K)	(24.7K)
Net Tangible Assets	1.5M	1.5M	3.1M	86.4M	99.3M	104.3M
Net Invested Capital	5.2M	6.7M	89.9M	72.7M	27.6M	30.4M
Net Working Capital	6.2K	1.6M	84.8M	67.6M	43.0M	27.6M
Capital Stock	163.9K	159.0	2.1K	2.2K	11.9M	12.5M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

When determining whether PharmaCyte Biotech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of PharmaCyte Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pharmacyte Biotech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Pharmacyte Biotech Stock:

How To Invest In PharmaCyte

Details

Is PharmaCyte Stock a good investment?

Details

What is PharmaCyte Biotech's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PharmaCyte Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

For information on how to trade PharmaCyte Stock refer to our How to Trade PharmaCyte Stock guide.

You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PharmaCyte Biotech. If investors know PharmaCyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PharmaCyte Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

0.64

Return On Assets

(0.05)

Return On Equity

0.4788

The market value of PharmaCyte Biotech is measured differently than its book value, which is the value of PharmaCyte that is recorded on the company's balance sheet. Investors also form their own opinion of PharmaCyte Biotech's value that differs from its market value or its book value, called intrinsic value, which is PharmaCyte Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PharmaCyte Biotech's market value can be influenced by many factors that don't directly affect PharmaCyte Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between PharmaCyte Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if PharmaCyte Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PharmaCyte Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

PharmaCyte Net Receivables vs Short Term Debt Analysis

Net Receivables vs Short Term Debt

Net Receivables vs Short Term Debt Correlation Analysis

Correlation Coefficient

Net Receivables

Short Term Debt

PharmaCyte Biotech fundamental ratios Correlations

PharmaCyte Biotech Account Relationship Matchups

High Positive Relationship

High Negative Relationship

PharmaCyte Biotech fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Common Stock	+ 1.0	Common Stock Total Equity
Non Currrent Assets Other	+ 1.0	Total Liab
Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Cash

Total Current Assets	- 1.0	Net Debt
Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Net Debt	- 1.0	Total Assets
Net Debt	- 0.99	Total Stockholder Equity
Short Term Investments	- 0.97	Inventory